The minds behind ArcticZymes Technologies

We, at ArcticZymes Technologies, are aware of the critical role enzymes play in research, diagnostics and therapeutics. This understanding drives our team of highly dedicated scientists and experienced managers to work with passion and dedication at the highest level to exceed the expectations of our partners.

The management team

Image

Dr Jethro Holter, CEO

Dr Jethro Holter (born 1972) joined ArcticZymes as Managing Director on January 1st, 2015 and was appointed interim CEO on October 23rd 2019 and then became permanent CEO on 22nd April, 2020. He has previous experience from Life Technologies (Thermo Fisher Scientific) in international business development of B2B/OEM solutions with Diagnostic and Life Science companies as well as other commercial experience. Earlier in his career, he was R&D Director at Mole Genetics AS developing automated sample prep solutions. Jethro Holter holds a Ph.D in Molecular Neuroscience from Cardiff University, UK. Number of shares in ArcticZymes Technologies held by Dr Holter: 564. Number of options in ArcticZymes Technologies held by Dr Holter: 200,000 (right to receive options on certain milestones)

Børge Sørvoll, CFO

Børge Sørvoll (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a "Siviløkonom" degree in Finance from the University of Wyoming. Number of shares in ArcticZymes Technologies held by Mr. Sørvoll: 25,428. Number of options in ArcticZymes Technologies held by Mr. Sørvoll: 200,000 (right to receive options on certain milestones)

Image
Image

Dr. Olav Lanes, Director R&D and Applications

Dr Lanes (born 1972) was granted a Dr Scient degree in molecular biology from University of Tromsø in 2000. He joined the company (Biotec Pharmacon) as a researcher the same year and the position as Director of R&D and Applications since in 2016.  Olav has extensive experience in innovation management and product development. Dr. Lanes is inventor and co-inventor of eight patent- or pending patent families, all today part of the IPR assets in the company.  Number of shares in ArcticZymes Technologies held by Dr Lanes: 2000. Number of options in ArcticZymes Technologies held by Dr Lanes: 0.

 

 

Dino DiCamillo, Director Marketing

Mr. DiCamillo (born 1958) joined ArcticZymes in 2012 as a commercial consultant and subsequently assumed the role of Director of Marketing for the organization.  He has previous experience as V.P of Advanced Research Technologies, President of Alfa Wassermann Proteomics, CCO of Dynal Biotech, and Senior Director of Applied Biosystems among other commercial and business related roles.  Dino is the President of Percorso Life Sciences and Scoperta Life Sciences and serves as a Director of Solentim Inc., Nordic BioSite Inc., PCR Biosystems Inc., and Hycult Biotech Inc.  Dino holds a B.S. in Biological Sciences and a M.B.A. from Temple University in Philadelphia. Number of shares in ArcticZymes Technologies held by Mr. DiCamillo: 0. Number of options in ArcticZymes Technologies held by Mr. Camillo: 0.

Image
Image

Dr. Marit Sjo Lorentzen, Director Operations

Dr Lorentzen (born 1968) was granted a Dr Scient degree in Biotechnology from University of Tromsø in 2005. She joined the company (Biotec Pharmacon) as a Sr. Research Scientist in 2011 and holds the position as Director of Operations since 2020.  She has extensive work experience within laboratory operations, management and research.. She is employee elected to The Board of Directors in ArcticZymes Technologies. Number of shares in ArcticZymes Technologies held by Dr Lorentzen: 20,331. Number of options in ArcticZymes Technologies held by Dr Lorentzen: 15,000.

 

The board of directors

Image

Dr Marie Ann Roskrow, Chairman

Dr Roskrow gained a BSc (Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Number of shares in ArcticZymes Technologies held by Dr Roskrow: 0. Number of options in ArcticZymes Technologies held by Dr. Roskrow: 200,000

Volker Wedershoven, Director

Mr. Wedershoven has a MBA from Ludwig-Maximilians-University, Munich, Germany and has a wide background within entrepreneurship, finance and strategy. Mr. Wedershoven has more than 30 years of industrial experience and was amongst others responsible for development of Seidenader Machinenbau, a global supplier of production equipment to the pharmaceutical industry. He sold the company in 2010 with close to 500 employees to a large equipment supplier in Germany. Mr. Wedershoven holds several board and management positions in smaller German companies. Number of shares in ArcticZymes Technologies held by Mr. Wedershoven: 80,000. Number of options in ArcticZymes Technologies held by Mr. Wedershoven: 100,000

Image
Image

Dr Marit Sjo Lorentzen, Director – employee representative

Dr Lorentzen has a Civil engineering degree in Biotechnology and a Dr. Scient in Molecular Biology degree from the University of Tromsø. Marit worked at the University of Tromsø until 2011. She has extensive work experience within laboratory operations, management and research. This also includes experience within teaching, field of studies in biochemistry, molecular biology, microbiology, fermentation and purification. She holds a position as Director of Operations in ArcticZymes Technologies. Number of shares in ArcticZymes Technologies held by Dr Lorentzen: 20,331. Number of options in ArcticZymes Technologies held by Dr Lorentzen: 15,000